Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

• Autores principales: Jiali Wang (Autor), Xianhai He (Autor), Zhirong Jia (Autor), Aiwen Yan (Autor), Kang Xiao (Autor), Shuo Liu (Autor), Mengjun Hou (Autor), Yaling Long (Autor), Xuansheng Ding (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

AbstractContext Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI) is widely accepted as an adjuvant therapy...